Benzinga | Aug 25, 2021 02:30PM EDT

BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV

* Becton Dickinson and Co (NYSE:BDX) has received FDA approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus (HPV).

* The modular and scalable BD Cor includes an automated sample preparation system, BD Cor PX, and an instrument that automates the BD Onclarity HPV assay, BD Cor GX.

* The PX instrument enables the preparation of specimens for testing.

* The BD Cor enables the processing of samples directly from liquid-based cytology vials, as well as the creation of molecular aliquot tubes and assay testing, automating labor-intensive and error-prone manual processes.

* The Cor has onboard capacity for reagents and samples to provide six to eight hours of system processing.

* The BD Cor was initially launched in Europe in 2019.

* Related content: Benzinga's Full FDA Calendar.

* Price Action: BDX shares are down 0.19% at $247.39 during the market session on the last check Wednesday.